-
1
-
-
49649115490
-
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostatespecific antigen, pain, and quality of life response and survival in the TAX-327 study
-
Berthold D, Pond G, Roessner M, de Wit R, Eisenberger M, Tannock I. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostatespecific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008;14(9):2763-2767.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.9
, pp. 2763-2767
-
-
Berthold, D.1
Pond, G.2
Roessner, M.3
de Wit, R.4
Eisenberger, M.5
Tannock, I.6
-
2
-
-
65349151253
-
Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease
-
Mostaghel E, Montgomery B, Nelson P. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol 2009;27(3):251-257.
-
(2009)
Urol Oncol
, vol.27
, Issue.3
, pp. 251-257
-
-
Mostaghel, E.1
Montgomery, B.2
Nelson, P.3
-
3
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005.
-
(2011)
N Engl J Med
, vol.364
, Issue.21
, pp. 1995-2005
-
-
de Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
-
4
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-1197.
-
(2012)
N Engl J Med
, vol.367
, Issue.13
, pp. 1187-1197
-
-
Scher, H.I.1
Fizazi, K.2
Saad, F.3
-
5
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-422.
-
(2010)
N Engl J Med
, vol.363
, Issue.5
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
6
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369(3):213-223.
-
(2013)
N Engl J Med
, vol.369
, Issue.3
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
-
7
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
-
de Bono J, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 2010;376(9747):1147-1154.
-
(2010)
Lancet
, vol.376
, Issue.9747
, pp. 1147-1154
-
-
de Bono, J.1
Oudard, S.2
Ozguroglu, M.3
-
8
-
-
79957497548
-
Expanding treatment options for metastatic prostate cancer
-
Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011;364(21): 2055-2058.
-
(2011)
N Engl J Med
, vol.364
, Issue.21
, pp. 2055-2058
-
-
Antonarakis, E.S.1
Eisenberger, M.A.2
-
9
-
-
84872078210
-
Abiraterone in metastatic prostate cancer without previous chemotherapy
-
Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-148.
-
(2013)
N Engl J Med
, vol.368
, Issue.2
, pp. 138-148
-
-
Ryan, C.J.1
Smith, M.R.2
de Bono, J.S.3
-
10
-
-
79953099043
-
Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm
-
Garcia J, Dreicer R. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Oncology (Williston Park) 2011;25(3):242-249.
-
(2011)
Oncology (Williston Park)
, vol.25
, Issue.3
, pp. 242-249
-
-
Garcia, J.1
Dreicer, R.2
-
11
-
-
84878601468
-
Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial
-
Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology 2013;81(6):1297-1302.
-
(2013)
Urology
, vol.81
, Issue.6
, pp. 1297-1302
-
-
Schellhammer, P.F.1
Chodak, G.2
Whitmore, J.B.3
Sims, R.4
Frohlich, M.W.5
Kantoff, P.W.6
-
12
-
-
84887055798
-
A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate plus prednisone in metastatic castrate-resistant prostate cancer
-
Small E, Lance R, Redfern C et al. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate plus prednisone in metastatic castrate-resistant prostate cancer. J Clin Oncol 2013;31:abstr 5047.
-
(2013)
J Clin Oncol
, vol.31
-
-
Small, E.1
Lance, R.2
Redfern, C.3
-
13
-
-
84882799782
-
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
-
Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24(7):1802-1807.
-
(2013)
Ann Oncol
, vol.24
, Issue.7
, pp. 1802-1807
-
-
Noonan, K.L.1
North, S.2
Bitting, R.L.3
Armstrong, A.J.4
Ellard, S.L.5
Chi, K.N.6
-
14
-
-
84888852048
-
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone
-
Schrader A, Boegemann M, Ohlmann C et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014;65(1):30-36.
-
(2014)
Eur Urol
, vol.65
, Issue.1
, pp. 30-36
-
-
Schrader, A.1
Boegemann, M.2
Ohlmann, C.3
-
15
-
-
84882789820
-
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
-
Loriot Y, Bianchini D, Ileana E et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24(7):1807-1812.
-
(2013)
Ann Oncol
, vol.24
, Issue.7
, pp. 1807-1812
-
-
Loriot, Y.1
Bianchini, D.2
Ileana, E.3
-
16
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock I, de Wit R, Berry W et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512.
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.1
de Wit, R.2
Berry, W.3
-
18
-
-
80055122242
-
A population-based study of prostate cancer chemotherapy
-
Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population-based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011;23(10):706-708.
-
(2011)
Clin Oncol (R Coll Radiol)
, vol.23
, Issue.10
, pp. 706-708
-
-
Harris, V.1
Lloyd, K.2
Forsey, S.3
Rogers, P.4
Roche, M.5
Parker, C.6
-
19
-
-
84878961883
-
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases
-
Lee RJ, Saylor PJ, Dror Michaelson M et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 2013;19(11):3088-3094.
-
(2013)
Clin Cancer Res
, vol.19
, Issue.11
, pp. 3088-3094
-
-
Lee, R.J.1
Saylor, P.J.2
Dror Michaelson, M.3
-
20
-
-
84880508629
-
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
-
Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013;24(7):1813-1821.
-
(2013)
Ann Oncol
, vol.24
, Issue.7
, pp. 1813-1821
-
-
Slovin, S.F.1
Higano, C.S.2
Hamid, O.3
-
21
-
-
80052468423
-
Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
-
Saad F, Hotte S, North S et al. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 2011;17(17):5765-5773.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.17
, pp. 5765-5773
-
-
Saad, F.1
Hotte, S.2
North, S.3
|